Open AccessResults from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
Author(s) -
Anne E. O’Shea,
Guy T. Clifton,
George E. Peoples
Publication year - 2021
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27998
Subject(s) - medicine , trastuzumab , triple negative breast cancer , oncology , targeted therapy , breast cancer , randomized controlled trial , cancer